Literature DB >> 1865782

The healthy-years equivalents: how to measure them using the standard gamble approach.

A Mehrez1, A Gafni.   

Abstract

The healthy-years equivalent (HYE) is a measure of outcome of health care programs that combines two outcomes of interest: quality of life and quantity of life. Unlike QALYs (quality-adjusted life years) HYEs fully represent patients' (or other individuals') preferences, as a result of the way they are calculated from each individual's utility function. The authors suggest an algorithm to measure the HYE of any given lifetime health profile. The algorithm is based on the classic standard gamble method to measure individuals' preferences under uncertainty, and consists of two lottery questions. Algorithms for the general case (any given lifetime health profile) and a simpler case--the chronic health state case--are provided, as is a modification of the algorithm aimed at shortening the length of the interview when an individual is faced with many possible lifetime health profiles. In addition, two questions are addressed. The first is theoretical and deals with the existence of HYE: do all lifetime health profiles, which are preferred to death, have hypothetical equivalents that can be measured in healthy years? The second is empirical and deals with the reproducibility of the measures obtained by using the measurement technique suggested. This is needed because the technique employs a combination of lottery questions that had not previously been used together. The results of an experiment performed to test the reproducibility of the measures were satisfactory.

Entities:  

Mesh:

Year:  1991        PMID: 1865782     DOI: 10.1177/0272989X9101100212

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  21 in total

Review 1.  Benefit valuation in economic evaluation of cancer therapies. A systematic review of the published literature.

Authors:  J Brown; M Sculpher
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 2.  Valuing health-related quality of life. A review of health state valuation techniques.

Authors:  C Green; J Brazier; M Deverill
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

Review 3.  Valuing health-related quality of life. Issues and controversies.

Authors:  P Dolan
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

4.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

5.  Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).

Authors:  A Mehrez; A Gafni
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

6.  Breast cancer: clinical decision making.

Authors:  J D Hayes; E J Clark
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

7.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

8.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 9.  Quality-of-life considerations in the treatment of asthma.

Authors:  E F Juniper
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

10.  A methodological guide to performing a cost-utility study comparing surgical techniques.

Authors:  Achilleas Thoma; Ted Haines; Karen Veltri; Charlie H Goldsmith; Bernie J O'Brien; Caroline Quartly
Journal:  Can J Plast Surg       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.